Treating diseases at their origin

Research Press Release | June 16, 2016

Hokkaido University scientists are getting closer to understanding the function of a protein involved in vital cellular processes. This may lead to the discovery of drugs that can treat some cancers and autoimmune disorders.

The protein STAT3 plays an important role in cell proliferation, survival and migration, making it an important modulator in inflammatory and malignant diseases. Mutations to the gene that signals its production can lead to a variety of diseases, including cancers and autoimmune disorders such as lymphoma, leukaemia, and childhood-onset autoimmunity. Understanding how STAT3 works is important to finding drugs that can treat these diseases.


Scientists at Hokkaido University in Japan investigated the molecular mechanisms that regulate STAT3 activity. They found that another protein, called ARL3, played an important role in the STAT3 pathway. By recognizing and strongly binding to STAT3, it facilitates the transportation of STAT3 into the nucleus and its accumulation there. In the nucleus, STAT3 then binds to special DNA sequences to regulate the turning on and off of certain genes.


HU16003fig1

Signaling cascade for STAT3 activation.

ARL3 binds to STAT3, facilitating its transportation and accumulation in the nucleus. JAKs induce the tyrosine phosphorylation of STAT3. The phosphorylated STAT3 forms a dimer and translocates from the cytoplasm to the nucleus where it binds to DNA and coactivators and induces gene transcription.


Inhibiting the expression of ARL3 in cultured cells led to a decrease in STAT3’s activity and consequently in the expression of its target genes. It also supressed STAT3-dependent proliferation of cells, indicating ARL3’s important regulatory role on STAT3 and its pathways.


Based on previous studies, the team believes that ARL3 might also influence certain proteins involved in the transfer of STAT3 and other molecules into and out of the nucleus. Additionally, they believe that ARL3 might regulate STAT3 by facilitating its interaction with microtubules, which help to transport substances within the cell.


“Clarifying each step of STAT3 regulation is important because STAT3 is a key player in the pathogenesis of diverse human diseases and is a prime target for novel therapies,” the researchers write in their study, published in the Journal of Biological Chemistry. “Specific inhibitors of the STAT3-ARL3 pathway are good candidates for the treatment of STAT3-related human diseases.”


Original Article:

A new STAT3-binding partner,ARL3,enhances the phosphorylation and nuclear accumulation of STAT3, The Journal of Biological Chemistry (04.05.2016)


Contacts:

Professor Tadashi MATSUDA

Department of Immunology

Graduate School of Pharmaceutical Sciences

Hokkaido University

tmatsuda[at]pharm.hokudai.ac.jp


Mr. Naoki NAMBA (Media Officer)

Global Relations Office

Office of International Affairs

Hokkaido University

Email: pr[at]oia.hokudai.ac.jp

Tel: +81-11-706-8034

LATEST NEWS

University News | December 15, 2017
Hokkaido Summer Institute 2018 courses finalized!
University News | December 13, 2017
Japan-Russia Youth Forum 2017 held at Hokkaido University
University News | December 01, 2017
HU Ambassador wins the 2017 Volvo Environmental Prize
University News | November 13, 2017
Dinner meeting with Indonesian alumni
Student Awards | November 10, 2017
Student Awards: Graduate School of Medicine

ARCHIVES

CONNECT WITH US

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn

BACK TO TOP